Journal: Journal of Cellular and Molecular Medicine

Article Title: Transcriptomics analysis of LINC02202 / XBP1 axis in melanoma: Implications for drug targeting and PD ‐1 monoclonal antibody efficacy

doi: 10.1111/jcmm.18247

Figure Lengend Snippet: The primer sequences information.

Article Snippet: The primary antibodies used in this study were diluted as follows: Cleaved‐caspase‐3 (1:1000, ab32042, Abcam), XBP1 (1:1500, 24,168‐1‐AP, Proteintech) and GAPDH (1:5000, ab9485, Abcam).

Techniques: Sequencing

Journal: Journal of Cellular and Molecular Medicine

Article Title: Transcriptomics analysis of LINC02202 / XBP1 axis in melanoma: Implications for drug targeting and PD ‐1 monoclonal antibody efficacy

doi: 10.1111/jcmm.18247

Figure Lengend Snippet: MiR‐526b‐3p could target XBP1. (A) The heatmap shows an overview of differentially expressed genes. (B) PCA analysis the difference of mRNA between the melanoma and melanocytic nevi. (C) Volcano plot analysis differentially expressed mRNAs in melanoma patients and the melanocytic nevi group. (D) Venn analysis of sequence data with targetscan. (E) The survival analysis the correction of XBP1 prognosis by Kaplan–Meier, data obtained from TCGA. (F) The survival analysis the correction of C8orf31 and C10orf25 prognosis by Kaplan–Meier, data obtained from TCGA.

Article Snippet: The primary antibodies used in this study were diluted as follows: Cleaved‐caspase‐3 (1:1000, ab32042, Abcam), XBP1 (1:1500, 24,168‐1‐AP, Proteintech) and GAPDH (1:5000, ab9485, Abcam).

Techniques: Sequencing

Journal: Journal of Cellular and Molecular Medicine

Article Title: Transcriptomics analysis of LINC02202 / XBP1 axis in melanoma: Implications for drug targeting and PD ‐1 monoclonal antibody efficacy

doi: 10.1111/jcmm.18247

Figure Lengend Snippet: LINC02202 could regulate miR‐526b‐3p/XBP1 axis. (A) The luciferase reporter assay for miR‐526b‐3p that directly targets the 3'UTR of XBP1. (B) The RT‐PCR detected that LINC02202 could regulate miR‐526b‐3p/XBP1 axis. (C) The Western blotting detected that LINC02202 could regulate miR‐526b‐3p/XBP1 axis. (D) Correlation analysis between LINC02202 and XBP1 expression. (E) Immunohistochemical detection of XBP1 and PD‐L1 expression in human melanoma tissue. ** p <0.01.

Article Snippet: The primary antibodies used in this study were diluted as follows: Cleaved‐caspase‐3 (1:1000, ab32042, Abcam), XBP1 (1:1500, 24,168‐1‐AP, Proteintech) and GAPDH (1:5000, ab9485, Abcam).

Techniques: Luciferase, Reporter Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot, Expressing, Immunohistochemical staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Transcriptomics analysis of LINC02202 / XBP1 axis in melanoma: Implications for drug targeting and PD ‐1 monoclonal antibody efficacy

doi: 10.1111/jcmm.18247

Figure Lengend Snippet: General characteristics of malignant melanoma patients.

Article Snippet: The primary antibodies used in this study were diluted as follows: Cleaved‐caspase‐3 (1:1000, ab32042, Abcam), XBP1 (1:1500, 24,168‐1‐AP, Proteintech) and GAPDH (1:5000, ab9485, Abcam).

Techniques: Expressing

Journal: Journal of Cellular and Molecular Medicine

Article Title: Transcriptomics analysis of LINC02202 / XBP1 axis in melanoma: Implications for drug targeting and PD ‐1 monoclonal antibody efficacy

doi: 10.1111/jcmm.18247

Figure Lengend Snippet: LINC02202 could regulate XBP1 axis affects immune killing in vivo. (A) Animal experimental design diagram. (B) Tumour image. (C) Tumour weight. (D) The IHC detection of ki‐67 and XBP1expression. (E) IF detection of CD8 expression.

Article Snippet: The primary antibodies used in this study were diluted as follows: Cleaved‐caspase‐3 (1:1000, ab32042, Abcam), XBP1 (1:1500, 24,168‐1‐AP, Proteintech) and GAPDH (1:5000, ab9485, Abcam).

Techniques: In Vivo, Expressing